Nanobiotix (NBTX) Receivables (2019 - 2025)

Nanobiotix's Receivables history runs 7 years deep, the most recent figure standing at $5.0 million for Q4 2025.

• On a quarterly basis, Receivables fell 21.8% year-over-year to $5.0 million in Q4 2025; TTM through Dec 2025 was $5.0 million, a 21.8% decrease from a year earlier, with the FY2025 full-year figure at $4.8 million, down 24.39% from the prior year.
• Receivables improved to $5.0 million in Q4 2025 per NBTX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Receivables topped out at $6.4 million in Q4 2024 and bottomed at -$9.0 million in Q2 2021.
• The 5-year median for Receivables is $2.7 million (2022), against an average of $1.7 million.
• Across the five-year window, Receivables soared 305.22% in 2024 and tumbled 60.98% in 2025, its largest moves.
• Year by year, Receivables stood at $3.9 million in 2021, then retreated by 24.97% to $2.9 million in 2022, then slipped by 13.8% to $2.5 million in 2023, then surged by 154.43% to $6.4 million in 2024, then slipped by 21.8% to $5.0 million in 2025.
• Per Business Quant, the three latest NBTX Receivables figures stand at $5.0 million (Q4 2025), $1.4 million (Q2 2025), and $6.4 million (Q4 2024).